Document is current

Article History

Received: 10 March 2025

Accepted: 17 July 2025

First Online: 9 August 2025

Declarations

:

: Carlos López-López reports receiving personal honoraria as an invited speaker from Roche, Astra-Zeneca, MSD, BMS, EISAI, Lilly, Ipsen; receiving payment for expert testimony from Roche, Astra-Zeneca, MSD, BSM, EISAI, Ipsen; receiving support for travel and/or meeting attendance from Roche, Astra-Zeneca, MSD, BMS, Ipsen; and participating on data safety monitoring boards or advisory boards for Roche, Astra-Zeneca, MSD, BMS, EISAI, Lilly, Ipsen. Paula Cerdá reports receiving personal honoraria as an invited speaker from Astra Zeneca and Roche; receiving support for travel from Roche and Eisai; and participating on data safety monitoring boards or advisory boards for Astra Zeneca. Mariona Calvo reports receiving personal honoraria as an invited speaker from Roche, Astra Zeneca, BMS.MSD and Eisai; receiving support for travel from Roche; and participating on data safety monitoring boards or advisory boards for Roche and Eisai. Beatriz García Paredes reports receiving personal honoraria as an invited speaker from Astra Zeneca; receiving support for travel from Roche; and participating on data safety monitoring boards or advisory boards for Roche. Miriam Lobo de Mena reports receiving honoraria from Servier, Leo Pharma and Incyte; receiving support for travel, accommodations and expenses from Astra Zeneca, Novartis, Ipsen, Servier, Pharma Mar and Roche. Jorge Adeva reports receiving support for travel from Roche; and participating on data safety monitoring boards or advisory boards for Roche and Astra Zeneca. Ana Ruiz-Casado reports receiving personal honoraria as an invited speaker from Medtronic; receiving support for travel from Servier; and participating on data safety monitoring boards or advisory boards for Amgen. Teresa García-García reports receiving personal honoraria as an invited speaker from Roche, Servier and Astra Zeneca; receiving support for travel from Servier. Roberto Pazo-Cid reports receiving personal honoraria as an invited speaker from Amgen, Astellas Pharma, Bristol Myers Squibb, Eisai, Eli Lilly, and Roche; receiving payment for expert testimony from AstraZeneca, Bristol Myers Squibb, and Eli Lilly; receiving support for travel and/or meeting attendance from Astellas Pharma, Bristol Myers Squibb, Eli Lilly, and Roche; and participating on data safety monitoring boards or advisory boards for AstraZeneca, Ipsen, and Roche. Javier Sastre reports receiving personal honoraria as an invited speaker from Roche, Lilly, Servier, MSD, Amgen, Eisai, BMS, Pierre-Fabré and Astellas; receiving support for travel and/or meeting attendance from Merck, Roche, Servier and Astellas; and participating on data safety monitoring boards or advisory boards for Roche, Servier, BMS, Astellas, Lilly, Pierre-Fabré, Astra-Zeneca and Boehringer. Eva Martínez de Castro, Ana Fernández Montes, Encarnación Jiménez Orozco, Sandra López Peraita, Ruth Vera, Adelaida La Casta, Javier Gallego, Juana Mª Cano Cano, Rosario Vidal-Tocino and Mercedes Rodríguez Garrote declare that they have no conflict of interest.

: This retrospective non-interventional study was conducted in compliance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations. The study was granted regulatory classification as non-EPA by the Spanish competent authority (AEMPS) on the 22nd June 2020, and the central ethics committee approval by the Ethics Committee of HUCA on the 18th August 2020 (code: 2020.317).

: Informed consent was obtained from all living patients prior to their inclusion in the study. For patients who had died prior to the study’s initiation, their participation was approved by the Ethics Committees.